is involved in haematopoietic growth factor signalling, JAK1, JAK3, and TYK2 are involved in immune system response and pro-inflammatory cytokines signalling. [2] [3] [4] This wide range of actions determines the clinical features of MF that is characterized by splenomegaly, constitutional symptoms, bone marrow fibrosis, and increased risk of developing infectious complications. [5] [6] [7] [8] Ruxolitinib (RUX) (JAKAVI, Novartis; JAKAFI, Incyte Corporation) represents the first-in-class JAK1/2 inhibitor. By blocking JAK-STAT signalling, RUX has demonstrated efficacy in reducing splenomegaly and ameliorating constitutional symptoms in 2 large phase III studies (COMFORT trials). 5, 9, 10 As expected, anaemia and thrombocytopenia were the most common side effects, mediated by JAK2 inhibition. In parallel, JAK1 inhibition is responsible for decrease in pro-inflammatory cytokines resulting in decrease of disease-related symptoms but also in impaired immune function. 11 Indeed, several abnormalities both in adaptive and innate immunity were demonstrated after RUX exposure. [12] [13] [14] [15] [16] From a clinical point of view, opportunistic and atypical infections have been described and an increase in urogenital, respiratory tract infections together with Herpes virus reactivations, are well-known on RUX therapy. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] We recently led an
Italian multicenter study on 507 MF patients reporting that RUX-exposed patients had a double risk of developing infections. 29 Taken together, these reports have raised the concern that a stricter anti-infectious surveillance and prophylaxis may be needed in case of RUX therapy. 30 For a proper management of MF patients eligible for RUX therapy, the identification of baseline risk factors for infections is becoming increasingly relevant.
Here, we retrospectively analysed a large cohort of MF patients treated with RUX to evaluate characteristics, outcome, and possible risk factors for infections. All grade ≥2 infections according to Common Terminology Criteria for Adverse Events (NCI-CTCAE) were recorded and they included bacterial, viral, mycobacterial, and fungal episodes. 39, 40 Bacterial, viral, and mycobacterial infections were confirmed by positive cultures derived from the suspected site of infection, elevation in pathogen-specific antibody titer and/or clinical manifestations including fever, increase in leukocytosis and acute-phase proteins and localized symptoms related to the potential source of the infection and that resolved with specific treatment.
| METHODS

| Patients and treatment
The study was conducted according to the Helsinki declaration.
| Statistical analysis
Clinical and laboratory parameters, as well as co-morbid conditions and MF treatments, were analysed as possible factors associated with infectious risk.
Categorical variables were compared using the chi-square or Fisher's exact test; continuous variables were compared using Wilcoxon rank sum tests.
A competing-risks method was used to analyse infection incidence. were negative for all the three driver mutations (triple-negative). In 18 out of 238 evaluable cases (8%), unfavourable cytogenetics were found, specifically: +8 (6 patients), −7 (3 patients), −5 (2 patients), 12p-(1 patient), 11q23 rearrangement (1 patient), and complex (5 patients).
Overall, 104 patients (23%) had a smoking habit, 45 (10%) diabetes.
Body mass index demonstrated underweight (score < 18) in 2% and overweight (score > 25) in 38% of patients. Before RUX start, 310
patients (70%) received cytoreductive therapy, mainly hydroxyurea (88%). Sixty patients (13%) were treated with a prolonged corticosteroid administration.
After a median follow-up of 46 months (range, 3-356) from MF diagnosis, 100 patients had died. Causes of death were represented by disease progression without acute transformation (37%), leukaemic evolution (17%), heart failure (9%), haemorrhage (7%), complications after allogeneic stem cell transplantation (4%), second neoplasms (2%), thrombosis (1%), and other unrelated causes (9%). In 14% of the cases, the infectious complication was the ultimate cause of death.
| Previous infectious history
A total of 40 patients (9%) presented a positive history of infectious complications before RUX administration. These infections involved respiratory tract (17) , skin (9), urogenital district (5) No patient received acyclovir prophylaxis because of previous herpes infections.
Two hundred and thirty-five patients were screened for Mycobacterium tuberculosis latent infection (quantiferon-TB). Three patients (3%) had positive quantiferon-test results, one of them received isoniazid therapy as prophylaxis during RUX therapy. The infections occurred more frequently soon after treatment starts: 14% of patients developed the first infection within 6 months, 
| RUX treatment
| Epidemiology of infectious complications
| Risk factors for infectious complications
Infections rate was higher in older patients (>65 y at RUX start) and when there was a longer time interval between MF diagnosis and RUX start. Also, the presence of a previous infectious complication correlated with higher infection incidence during RUX (Table 1) .
In univariate analysis, age at RUX start ≥65 years (P = .004), high IPSS risk score at RUX start (P = .028), Hb <10 g/dL (P = .03), 
| DISCUSSION
The risk of potentially severe infections represents one of the major concerns related to the use of RUX in patients with MF. This concern was first raised by the evidence that RUX-treated patients had a higher rate of infectious complications compared to controls in both registrative COMFORT trials. 9, 10 This observation was rapidly expanded by several clinical cases reporting atypical and opportunistic infections during RUX therapy, including Mycobacterium tuberculosis, HBV, CMV reactivations, and fungal infections. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] Finally, patients with PV treated with RUX experienced a significantly higher rate of herpes zoster virus reactivations. 41, 42 Here, we describe characteristics, outcome, and risk factors for infections in a large cohort of MF patients treated with RUX.
We documented that infections occurred in about a quarter of the population. This proportion is substantially lower compared to that reported in registrative trials that was around 50%. However, our study included patients treated in common practice and in expanded- As in previous prospective trials, bacteria were the most commonly involved pathogens and pulmonary infections were the most prevalent. The frequency and site of involvement were similar to those observed in our previous paper on general MF population. 29 Opportunistic infections were rarely observed: 3 cases of TBC were encountered in TB-quantiferon unscreened patients, 1 fungal pneumonia, 13 46 The rate of infections significantly decreased along the treatment exposition, as observed in prospective trials. Additionally, we did not find any significant correlation between RUX dosage and occurrence of infectious event. Conversely, the achievement of a significant spleen response (decrease by 50% at 3 mo) projected patients to a better infectious-free survival. Taken together, these findings reinforce the concept of disease severity as the most important risk factor for infections and describe, for the first time, that a positive therapeutic effect in reducing splenomegaly may also result in a benefit on infectious risk. The phase I-II study INCB18424-251 (NCT00509899) first assessed the beneficial effect of spleen response on survival, probably also thanks to a reduction of infectious episodes. 47 From a biological point of view, despite the previously described RUX-driven immune dysfunction, it can be argued that the reduction in extramedullary haematopoiesis could affect immune surveillance by positively remodelling the immune/inflammatory micro-environment in a currently unknown way.
We acknowledge that the retrospective nature of this study reduces the accuracy of infections recording. Also, the low rate of infections requiring hospitalization may have induced an underestimation of the events. However, the collection of a large cohort of MF patients treated with RUX for a long period provides useful information for the management of infectious risk in standard clinical practice and contributes to the identification of patients at higher infectious risk.
In conclusion, IPSS score and patient history identify MF patients with the highest risk of developing infections during RUX therapy. In these high-risk patients, the risk-benefit ratio of RUX use should be evaluated with particular attention. Importantly, RUX dosage was not found to be associated with infections
FIGURE 4
Three-month landmark analysis of infection-free survival according the obtainment of spleen reduction ≥50% from baseline (BL) at 3 mo. The analysis is adjusted for IPSS category. Red line identifies patients achieving a ≥50% spleen reduction at 3 mo from baseline, black line nonresponder patients occurrence; conversely, the achievement of spleen response was a positive predictive factor for infection-free survival. Finally, a more conscious management of the infectious risk by widespread antiinfectious screening and prophylaxis seemed to reduce the occurrence of opportunistic infections compared to previous reports.
Therefore, this crucial clinical aspect should be standardized and implemented, possibly in prospective clinical trials.
